Last $0.13 USD
Change Today -0.01 / -7.15%
Volume 81.7K
HEPI On Other Exchanges
As of 12:35 PM 07/30/14 All times are local (Market data is delayed by at least 15 minutes).

health enhancement products (HEPI) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/7/13 - $0.50
52 Week Low
07/28/14 - $0.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

health enhancement products (HEPI) Related Businessweek News

No Related Businessweek News Found

health enhancement products (HEPI) Details

Health Enhancement Products, Inc., a biotech company, engages in the investigation of the health benefits of bioactive compounds derived from its proprietary algal cultures. The company is also involved in the development of natural bioactive compounds for use as dietary supplements and food ingredients, as well as potential candidates for future medicinal and pharmaceutical applications in humans and animals, focused on autoimmune modulation. Its intellectual property consists of the algae culture, the patented process of producing that culture; and the bioactive compounds or molecules that can be extracted, as well as the application of that culture or extracts to a particular condition or disease. Health Enhancement Products, Inc. is based in Keego Harbor, Michigan.

health enhancement products (HEPI) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: $240.0K
Chief Financial Officer and Director
Total Annual Compensation: $184.5K
Compensation as of Fiscal Year 2013.

health enhancement products (HEPI) Key Developments

Health Enhancement Products, Inc. Announces Increase in Credit Facility

Health Enhancement Products, Inc. announced that its primary lender has increased the company's credit facility to $6 million, making $1 million available immediately to expedite both canine and bovine validation studies currently underway in the United States and Canada.

Health Enhancement Products, Inc. Announces Preliminary Research Results for Efficacy in Supporting Canine Joint Health

Health Enhancement Products, Inc. announced preliminary research results for efficacy in supporting canine joint health. The research was conducted at Covance Inc., based in Princeton, New Jersey. Joint health issues are predicted to affect nearly 1 in 5 dogs, and the canine joint health supplement market generates roughly $300 million in annual sales in the US alone. The research study, a canine whole-blood assay, involves experimentally inducing a state of inflammation in a process that mimics the conditions observed in dogs with osteoarthritis, in order to investigate the anti-inflammatory properties of HEPI's compounds. Canine osteoarthritis is a complex disease caused by the degradation of cartilage tissue. The assay measured Prostaglandin E2 (PGE2), a biological mediator of inflammation and target for inhibiting aggressive or prolonged immune responses. The initial results of the study indicate that naturally-produced HEPI compounds significantly reduce the stimulated release of PGE2 in canine whole blood -- in other words, the HEPI compounds were shown to reduce the release of a substance that contributes to pain and inflammation in osteoarthritis. These results support prior HEPI research, which demonstrated significant reduction of acute inflammation in a similar animal model. These clinically significant results are compelling evidence for the anti-inflammatory effects of HEPI's compounds, and are another step in establishing the safety and efficacy of supplements for the dog joint health market. Further research with Covance to repeat these findings in a larger group and to explore the anti-inflammatory mechanisms of HEPI compounds will be underway shortly. In the interim, these results and others are being shared with potential development partners. The company has also commenced a follow-on study with the University of Missouri to further substantiate the positive effects of its bioactive compounds in supporting canine joint health.

Health Enhancement Products, Inc. Enters into Collaborative Agreement with Global Animal Health Company to Accelerate Bovine Mastitis Product

Health Enhancement Products, Inc. entered into a collaborative/option agreement with a global animal health company. The terms of the agreement will allow Health Enhancement Products to move forward with validation and product development in direct collaboration with scientists from the animal health company. At pre-determined intervals of 90 days each for an evaluation period and a negotiation period which may culminate in a final licensing arrangement, additional opportunities to further disclose aspects of the agreement may occur. The agreement provides for a licensing option covering bovine applications across a range of modalities, and includes the Company's natural compound, the proprietary refined algal extract and the synthetic molecules developed by Health Enhancement.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HEPI:US $0.13 USD -0.01

HEPI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HEPI.
View Industry Companies

Industry Analysis


Industry Average

Valuation HEPI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HEALTH ENHANCEMENT PRODUCTS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at